

HBsAg Strip Rapid Test

(Serum / Plasma)

INTENDED USE

First View HBsAg Strip Rapid test is a lateral flow immunoassay and qualitative screening, In-Vitro diagnostic immune-chromatographic assay for detection of antigen specific to HBsAg Antibodies in human serum/plasma.

INTRODUCTION

Hepatitis B surface antigen ("Australis Antigen") consists of lipid, carbohydrate and protein elements; the protein moiety provides a marker for identification of chronic, infectious HBV infections. Hepatitis B is transmitted sexually or intravenously and has an incubation period of six months. If not diagnosed properly and in time, it can develop into acute or chronic infection, liver cirrhosis and fulminant Hepatitis. This test is very useful for screening blood donors, to find out whether they are HBsAg positive before collection of blood.

PRINCIPLE OF TEST

HBsAg Strip test utilizes the principle of immunochromatography, a unique assay based on antigen capture or sandwich principle. The method uses monoclonal antibody conjugated to colloidal gold and polyclonal antibodies immobilized on nitrocellulose strip in thin line. As the test sample flows through the membrane assembly of the test strip, the colored monoclonal anti-HBsAg-colloidal gold conjugate complexes with the HBsAg in the sample. This complex moves further on the membrane to the test region where it is immobilized by a polyclonal anti HBsAg antiserum coated on the membrane leading to formation of pink-purple colored band. The formation of first purple band (T zone) confirms a positive test result. Absence of this colored band in the test region indicates a negative test result. The unreacted conjugate and unbound complex, if any, move further on the membrane subsequently immobilized by the anti-rabbit IgG coated on the membrane at the control region, forming a pink-purple band. This control band serves to validate the test results.

REAGENTS AND MATERIALS PROVIDED

HBsAg Strip test contain the following:

- Test strip with activated silica gel
- Package Insert (Instruction for use)

MATERIALS REQUIRED BUT NOT PROVIDE

- Positive Control
- Negative Control
- Timer
- Digital Clock

WARNINGS AND PRECAUTIONS:

For professional in Vitro Diagnostic Use

- This package insert must be read completely before performing the test.
- The test strip should remain in the sealed pouch until use
- Do not use expired test strip.
- Do not use the kit if the strip package is damaged or the seal is broken.
- Bring all reagent to room temperature (15-30°C) before use.
- Do not use hemolyzed blood specimens for testing.
- Wear personal protective equipment, such as gloves and lab coats when handling kit reagents. Wash hands thoroughly after performing the test.
- Do not smoke, drink or eat in areas where specimens or kit reagents are being handled.
- Dispose of all specimens and material used to perform the test as bio-hazardous waste.

REAGENT PREPARATION AND STORAGE

INSTRUCTIONS: All reagents are ready to use as supplied. Store unused test device unopened at 2-30 °C; ensure that the test Strip brought to room temperature before opening. The test device is

stable through the expiration date printed on the sealed pouch. Do not freeze the kit or expose the kit to temperature 30°C.

SPECIMEN COLLECTION, STORAGE AND HANDLING

Consider any materials of human origin as infectious and handle them using standard bio-safety procedures.

1. Plasma

- **Step 1:** Collect blood specimen into a lavender, blue or green top collection tube (containing EDTA, citrate or heparin, respectively, in Vacutainer®) by venipuncture.
- **Step 2:** Separate the plasma by centrifugation.
- **Step 3:** Carefully withdraw the plasma into a new pre-labeled tube.

2. Serum


- **Step 1:** Collect blood specimen into a red top collection tube (containing no anti coagulants in Vacutainer®) by venipuncture.
- **Step 2:** Allow the blood to clot.
- **Step 3:** Separate the serum by centrifugation.
- **Step 4:** Carefully withdraw the serum into a new pre-labeled tube.

Test specimens as soon as possible after collecting. Store Specimens at 2-8°C if not tested immediately, for up to 5 days. The specimens should be frozen at -20°C for longer storage.

DIRECTIONS FOR USE

Allow test Strip Pouch, specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

- Bring the pouch to room temperature before opening it.
- Remove the test strip from the sealed pouch and use it as soon as possible.
- Collect at least 150µL of serum or plasma in a sample container.
- With arrows pointing toward the specimen, dip the strip into the specimen and start the timer.
- Don't allow the specimen to reach above the maximum level (**MAX**) indicated by the arrows on the strip.
- Wait for the colored line(s) to appear. The result should be read at 10-15 minutes.



INTERPRETATION OF ASSAY RESULT

Negative Result: If only the control (C) band is developed, the test indicates that no detectable HBsAg antigen is present in the specimen. The result is negative.

Positive Result: If the both control (C) and test band (T) are developed, the test indicates for the presence of HBsAg antigen in specimen. The result is HBsAg Positive.

Invalid Result: If no control band is developed the assay is invalid regardless of color development on T bands. Repeat the assay with a new strip.

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that a positive control (containing 10ng/mL HBsAg) and a negative control (containing 0 ng/mL HBsAg) be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

PERFORMANCE CHARACTERISTICS

1. Sensitivity & Specificity

First View HBsAg Strip Rapid test has been tested using in-house panel of positive and negative clinical samples confirmed by leading commercial anti HBsAg ELISA and lateral Flow test and the correlation between these two systems was found to be 100%.

Method	ELISA			Total Results
	Results	Positive	Negative	
First View HBsAg Strip Rapid Test (Serum/Plasma)	Positive	200	0	200
	Negative	0	1000	1000
Total Results		200	1000	1200

Relative Sensitivity: -100%

Relative Specificity: - 100%

Accuracy : - 100%

2. Cross-reactivity

The HBsAg Strip Rapid Test (Serum/Plasma) has been tested by HAMA, Rheumatoid factor (RF), HAV, and Syphilis, HIV, H. Pylori, MONO, CMV, Rubella and TOXO positive specimens. The results showed no cross-reactivity.

3. Interfering Substances

The HBsAg Strip Rapid Test (Serum/Plasma) has been tested for possible interference from visibly hemolyzed and lipid specimens. No interference was observed.

In addition, no interference was observed in specimens containing up to 2,000 mg/dL Hemoglobin, 1000 mg/dL Bilirubin, and 2000 mg/dL human serum Albumin,

LIMITATIONS AND INTERFERENCES

- This is only a screening test to detect the presence of antigen against HBsAg antibodies. All specimens detected reactive must be cross checked by using other techniques like ELISA, PCR.
- A definitive clinical diagnosis should not be based on the single test. But should only be made by the physician after all clinical and laboratory findings have been evaluated.
- A positive test result must be verified with a confirmatory test.
- This test is designed for use with serum/plasma samples only. Use of other body fluids, including urine or saliva has not been established.
- A negative result can occur if the quantity of the analyte of interest present in the specimen is below the detection limits of the assay or the analyst of interest that are detected and not present during the stage of disease in which a sample is collected.

WASTE MANAGEMENT OR DISPOSABLE

The contents of RDTs can be divided into:

Infectious waste:

- sharps (lancets, needles, scalpel blades)
- blood collection devices (tubes, straws, and loops); gloves; swabs; and cotton & used devices.

Non-infectious waste (Recyclable):

- Packaging materials, desiccant, and unused or unusable RDTs. **"You must collect and dispose each type of waste in separate containers as per your waste management policies".**

LIMITED EXPRESS WARRANTY DISCLAIMER

Bioline Diagnostics LLP. Products are warranted to meet the applicable product specifications described. Notice of non-conforming products should be made to Bioline Diagnostics LLP. For which liability is limited to either replacement of the product and in no case liable to for claim of any kind for an amount greater than the purchase price of the goods in respect of which damages are likely to be claimed. Bioline Diagnostics LLP. Disclaims any and all responsibility for any injury or damage or legal implications which may be caused by the fault of the user or buyer in accordance with the limitations and specifications here in.

BIBLIOGRAPHY

1. CDC. Suboptimal Response to Hepatitis B Vaccine given by Injection into the Buttock. MMWR Weekly Report 1985; 34:105-8,113.
2. Centers for Disease Control and Prevention. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 2: Immunization of Adults, MMWR 2006, 55(RR-16): 1-25.
3. Stevens, C.E.; Taylor, P.E.; Tong, M.J., et al.: Prevention of Perinatal Hepatitis B Virus Infection with Hepatitis B Immune Globulin and Hepatitis B Vaccine, in Zuckerman, A.J. (ed.), "Viral Hepatitis and Liver Diseases", Alan R. Liss, 982-983,1988.
4. Stevens, C.E.; Taylor, P.E.; Tong, M.J., et al.: Yeast-Recombinant Hepatitis B Vaccine, Efficacy with Hepatitis B Immune Globulin in Prevention of Perinatal Hepatitis B Virus Transmission, JAMA 257(19): 2612-2616, 1987.
5. Beasley, R.P.; Hwang, L.; Stevens, C.E.; Lin, C.; Hsieh, F.; Wang, K.; Sun, T.; Szmuness, W.: Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized DoubleBlind, Placebo-Controlled Trial, Hepatology 3:135-141,1983.
6. Wiedmann, M.; Liebert, U.G.; Oesen, U.; Porst, H.; Wiese, M.; Schroeder, S.; Halm, U.; Mossner, J.; Berr, F.: Decreased Immunogenicity of Recombinant Hepatitis B Vaccine in Chronic Hepatitis C, Hepatology, 31: 230-234, 2000.
7. Minniti, F.; Baldo, V.; Trivello, R.; Bricolo, R.; Di Furia, L.; Renzulli, G.; Chiaramonte, M.: Response to HBV vaccine in Relation to anti-HCV and anti-HBc Positivity: a Study in Intravenous Drug Addicts, Vaccine, 17: 3083-3085, 1999.